title: Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
abstract: Recently radiolabeled ligands targeting prostate specific membrane antigen (PSMA) have been introduced for diagnostics and treatment of prostate cancer. Labeled with Lutetium, PSMA radioligand therapy (RLT) is one of the most promising new treatments of metastatic castration refractory prostate cancer. We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases. Furthermore, this case shows that CT is of no use in assessing response in bone metastases of prostate cancer.
authors.affiliation: From the Departments of *Nuclear Medicine, and †Urology University Hospital Münster, Münster, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Roll
authors.forename: Axel
authors.initials: A
authors.lastname: Bode
authors.forename: Matthias
authors.initials: M
authors.lastname: Weckesser
authors.forename: Martin
authors.initials: M
authors.lastname: Bögemann
authors.forename: Kambiz
authors.initials: K
authors.lastname: Rahbar
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000556:secondary; D004151:Dipeptides / Q000627:therapeutic use*; D004492:Edetic Acid / Q000031:analogs & derivatives; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D009842:Oligopeptides; D009942:Organometallic Compounds; D000072078:Positron Emission Tomography Computed Tomography; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
chemical_list: C000610110:Pluvicto; D004151:Dipeptides; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006573:Heterocyclic Compounds, 1-Ring; D009842:Oligopeptides; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D008187:Lutetium; D004492:Edetic Acid; D017430:Prostate-Specific Antigen